Common Side Effects of Lurbinectedin Treatments
Lurbinectedin is a medication used to treat certain types of cancer, including small cell lung cancer [1]. While it can be an effective treatment, like all medications, it can also cause side effects. According to clinical trial data and patient reports, some common side effects of lurbinectedin treatments include [2]:
- Fatigue: Feeling extremely tired or weak is a common side effect of lurbinectedin. This can be due to the medication's effect on the body's overall energy levels or the cancer itself.
- Nausea and Vomiting: Lurbinectedin can cause nausea and vomiting in some patients, which may be due to inflammation in the lining of the digestive tract.
- Diarrhea or Constipation: Some patients may experience changes in their bowel movements, such as diarrhea or constipation, due to the medication's impact on the digestive system.
- Abnormal Liver Function Tests: Elevated liver enzyme levels have been reported in some patients taking lurbinectedin, which can be a sign of liver damage [3].
- Low White Blood Cell Count: Lurbinectedin can cause a decrease in white blood cell count, making patients more susceptible to infection.
- Decreased Appetite: Some patients may experience a reduction in appetite due to the medication's side effects or the cancer itself.
Less Common but Serious Side Effects
While rare, some patients may experience more serious side effects, including [2]:
- Prolonged QT Interval: Lurbinectedin can cause an abnormal prolongation of the QT interval, which can lead to life-threatening arrhythmias.
- Liver Damage: Rare cases of liver damage, including liver failure, have been associated with lurbinectedin treatment [3].
- Severe allergic reactions: Patients may experience severe allergic reactions, including anaphylaxis, which can be life-threatening if not treated promptly.
Monitoring and Prevention
To minimize the risk of side effects, patients taking lurbinectedin should be closely monitored by their healthcare provider. Regular blood tests can help detect potential liver damage or changes in white blood cell count. Patients should also report any side effects they experience to their healthcare provider promptly.
Sources:
[1] ClinicalTrials.gov (2023). Lurbinectedin for the Treatment of Small Cell Lung Cancer.
[2] Novartis Pharmaceuticals Corporation. (n.d.). Lurbinectedin Prescribing Information.
[3] European Medicines Agency (EMA) (2020). Lurbinectedin (Zepzelca) - EPAR Product Information.